SHARDACROP: Q2 growth was broad-based, while H2 recovery underpins unchanged FY27 guidance

What happened

Sharda Cropchem reported that Q2 revenue grew 13% and profit after tax (PAT) rose 23% year over year. Strong performance in North America and Latin America offset softer Europe. It kept FY27 guidance unchanged, forecasting 10%-15% revenue growth and an 18%-20% EBITDA margin, supported by an expected second-half recovery and registration-led launches.

Confirmed

Global impact / market context

The unchanged forecast makes the expected second-half recovery important: if it occurs, it could help sustain revenue growth and the company’s expected EBITDA margin, a measure of operating profit relative to revenue. If recovery or launches fall short, the guidance may be harder to achieve.

Analyst inference

The quarter showed different regional trends, with North America and Latin America growth offsetting weaker Europe. That broad but uneven performance may matter to investors because the full-year outlook depends not only on recent growth but also on a recovery later in the year.

Analyst inference

What to watch

1. Whether second-half revenue improves as expected; that recovery is a stated support for unchanged FY27 guidance of 10%-15% revenue growth. Analyst inference
2. Whether registration-led launches proceed and contribute to sales, since the company cites them as another support for its FY27 outlook. Analyst inference
3. Whether Europe’s softer performance persists or improves, and whether North America and Latin America continue to offset it in subsequent results. Analyst inference

Evidence

• Original source link unavailable